- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06714097
Aplicación de la tecnología de gemelos digitales en pacientes que sufrieron un accidente cerebrovascular, con enfermedad de Moyamoya y con angiopatía amiloide cerebral (CAA) durante la fase de prevención secundaria: una prueba de concepto mediante un ensayo de control aleatorio (estudio clínico 6, proyecto STRATIF-AI) (SMART)
The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes.
The main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform? Researchers will compare Arm 1, who use the STRATIF-AI app in addition to standard secondary prevention, against Arm 2, who receive standard secondary prevention only, to collect feedback regarding the platform usability.
Participants in the Arm 1 will:
- Complete cognitive and psychological assessments at the time of the first visit and after six months
- Follow the indications received from the clinician for standard secondary prevention
- Use the STRATIF-AI app daily for health management
- Optionally, purchase wearable devices that connect to the app.
- Participate in interviews at the six-month mark to share their experiences with the app.
Patients in the Arm 2 will:
- Complete cognitive and psychological assessments at the time of the first visit and after six months
- Follow the indications received from the clinician for standard secondary prevention
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
AIMS
Patients in secondary prevention with Moyamoya, CAA and stroke admitted to the Cerebrovascular Disease Unit of Carlo Besta Neurological Institute will be enrolled and randomized 1:1 in the following two arms:
- Arm 1 is the intervention group: patients allocated to this arm will receive the standard secondary prevention and will also use the STRATIF-AI app, which will integrate digital twin (DT) technology to improve patient management during the secondary prevention phase and to assist patients in understanding key concepts, such as: "Why should I care about a certain risk factor (e.g. blood pressure), and how can my lifestyle impact that risk factor? In other words, they will use the app to understand their medical situation, and to set personal goals.
- Arm 2 is the control group: patients allocated to this arm will receive only standard seconda prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA.
Patients will be screened and enrolled upon admission to the Cerebrovascular Disease Unit. They will complete a set of clinical, cognitive, and psychological evaluation, performed at the time point of enrolment (T0) and at a 6-months follow-up (T1).
Only for the Arm 1, a brief explanation about the use of the app will add about 30 minutes to the initial visit. Afterward, patients can use the app at their discretion to assist in self-care. The app also offers the option to connect to wearable devices.
This study involves the collection of quantitative and qualitative data as follows:
-
Quantitative data:
- Cognitive status will be evaluated with Montreal Cognitive Assessment (MOCA) test
- General health and disability status will be evaluated with Patient Reported Outcome Measures: Short Form Health Survey 36 (SF-36), WHO Disability Assessment Schedule (WHO DAS 2.0),
- Psychological status will be evaluated with Center for Epidemiologic Studies Depression Scales (CES-D), General Anxiety Disorder 7-Item (GAD-7), Fatigue Severity Scale, Impact of Event Scale Revised (IES-R).
- Clinical functioning will be evaluated using the modified Rankin scale (mRS) and the Clinical Functioning Information Tool (ClinFIT).
Moreover, we will collect clinical variables such as: TFNE (Transient Focal Neurological Episodes), headache, seizures, hypertension, diabetes mellitus, dyslipidemia, obstructive sleep apnea (OSA), ischemic heart disease, atrial fibrillation, smoke, weight, height, body Mass Index (BMI), sedentariness, current use of estrogens and progestins, hyperhomocysteinemia, previous head injury, previous neurosurgery, previous blood transfusion, comorbidities, current medical therapy.
- Data related to the index event will be collected: symptomatic or asymptomatic patient; type of index event, date of index event, age of onset, mRS for symptomatic patients.
- Socio-demographic data will be also collected (age, gender, birth date, age at the first visit, date of the visit, race, level of education).
-
Qualitative data Semi-structured interviews will be developed and perform at T1 to obtain feedback from the end users (patients and/or caregivers) of the DT to understand their user experience.
Qualitative analysis of user experiences will be the main focus. The NVivo software will be used to identify topics and perform advanced queries.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Matilde Leonardi, MD
- Número de teléfono: 2521 +39 02 2394 2511
- Correo electrónico: matilde.leonardi@istituto-besta.it
Copia de seguridad de contactos de estudio
- Nombre: Barbara Maistrello
- Número de teléfono: 2521 +39 02 2394 2521
- Correo electrónico: barbara.maistrello@istituto-besta.it
Ubicaciones de estudio
-
-
Michigan
-
Milan, Michigan, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Neurologico Carlo Besta
-
Contacto:
- Matilde Leonardi, MD
- Número de teléfono: +39 02 2394 2511
- Correo electrónico: matilde.leonardi@istituto-besta.it
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- People aged ≥ 18
- Clinical and neuroradiological diagnosis of stroke (TAC or MR); diagnosis of CAA based on Boston 2.0 criteria; diagnosis of Moyamoya disease based on diagnostic criteria 2021.
- MOCA total score ≥ 23
- modified Rankin Scale (mRS) ≤ 2
- First-time patients at the Besta Institute
- Ability to sign informed consent
- Possibility of performing a brain MRI
Exclusion Criteria:
- Patients with transient neurological deficits that resolve within an hour and normal brain imaging
- Patient under legal protection or deprived of liberty by judicial or administrative decision
- Patient whose follow-up will be impossible
- Contraindication to magnetic resonance imaging and/or Digital subtraction angiography (DSA)
- Pregnant patients
- Known or suspected drug or alcohol abuse
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Standard secondary prevention + digital twin
Patients allocated to this arm will receive the standard secondary prevention and will also use the STRATIF-AI app, which will integrate digital twin (DT) technology to improve patient management during the secondary prevention phase and to assist patients in understanding key concepts, such as: "Why should I care about a certain risk factor (e.g. blood pressure), and how can my lifestyle impact that risk factor? In other words, they will use the app to understand their medical situation, and to set personal goals. |
STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase |
|
Comparador activo: Standard secondary prevention only
Patients allocated to this arm will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA. |
Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feedback from users
Periodo de tiempo: 12 months
|
To get initial feedback on the patients' experience regarding the use of the STRATIF-AIplatform in the secondary prevention phase. |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
feedback to developers
Periodo de tiempo: 12 months
|
feedback to development team. This will be used as a starting point for future studiesand for conversations with other clinics, politicians, and policy maker. |
12 months
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Elkefi S, Asan O. Digital Twins for Managing Health Care Systems: Rapid Literature Review. J Med Internet Res. 2022 Aug 16;24(8):e37641. doi: 10.2196/37641.
- Herrgardh T, Madai VI, Kelleher JD, Magnusson R, Gustafsson M, Milani L, Gennemark P, Cedersund G. Hybrid modelling for stroke care: Review and suggestions of new approaches for risk assessment and simulation of scenarios. Neuroimage Clin. 2021;31:102694. doi: 10.1016/j.nicl.2021.102694. Epub 2021 May 7.
- Marwaa MN, Guidetti S, Ytterberg C, Kristensen HK. Using experience-based co-design to develop mobile/tablet applications to support a person-centred and empowering stroke rehabilitation. Res Involv Engagem. 2023 Aug 24;9(1):69. doi: 10.1186/s40900-023-00472-z.
- Prust ML, Forman R, Ovbiagele B. Addressing disparities in the global epidemiology of stroke. Nat Rev Neurol. 2024 Apr;20(4):207-221. doi: 10.1038/s41582-023-00921-z. Epub 2024 Jan 16.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades metabólicas
- Deficiencias de proteostasis
- Enfermedades arteriales oclusivas
- Enfermedades Arteriales Intracraneales
- Enfermedades de la arteria carótida
- Enfermedades Arteriales Cerebrales
- Amilosis
- Enfermedades Nutricionales y Metabólicas
- Carrera
- Enfermedad de Moyamoya
- Angiopatía amiloide cerebral
Otros números de identificación del estudio
- SMART
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .